Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.030
-0.110 (-9.65%)
At close: Feb 20, 2026, 4:00 PM EST
1.070
+0.040 (3.88%)
After-hours: Feb 20, 2026, 5:42 PM EST
Phio Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
11.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 21.00K | -117.00K | -84.78% |
| Dec 31, 2018 | 138.00K | 123.00K | 820.00% |
| Dec 31, 2017 | 15.00K | -4.00K | -21.05% |
| Dec 31, 2016 | 19.00K | -15.00K | -44.12% |
| Dec 31, 2015 | 34.00K | -37.00K | -52.11% |
| Dec 31, 2014 | 71.00K | -328.00K | -82.21% |
| Dec 31, 2013 | 399.00K | 302.00K | 311.34% |
| Dec 31, 2012 | 97.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 12.74M |
| BioAtla | 11.00M |
| Moolec Science | 7.83M |
| Traws Pharma | 2.85M |
| Longeveron | 1.44M |
| CytoMed Therapeutics | 573.19K |
| Iterum Therapeutics | 390.00K |
| BioCardia | 3.00K |
PHIO News
- 8 days ago - What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
- 10 days ago - Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Benzinga
- 10 days ago - Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - Newsfile Corp
- 25 days ago - Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - Newsfile Corp
- 3 months ago - Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile Corp